A Real-World, Observational Study Investigating Lenalidomide Maintenance (R-MT) Treatment after Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction and Stem Cell Transplant (SCT) in High-Risk (HR) Patients with Newly Diagnosed Multiple Myeloma (NDMM)
Phase of Trial: Phase IV
Latest Information Update: 24 Jun 2018
Price : $35 *
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 24 Jun 2018 New trial record
- 17 Jun 2018 Results (n=85) presented at the 23rd Congress of the European Haematology Association.
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.